MeSH term
Frequency | Condition_Probility | DNA Primers/chemistry | 2 | 0.0 |
Heparan Sulfate Proteoglycan/*genetics | 7 | 50.0 |
Humans | 52 | 0.0 |
Male | 19 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 46 | 0.0 |
Animals | 18 | 0.0 |
*Genes, Tumor Suppressor | 3 | 0.0 |
Mice | 12 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Rats | 5 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
*Mutation | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Adolescent | 2 | 0.0 |
Blotting, Western | 5 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 2 | 0.0 |
Female | 19 | 0.0 |
Infant | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Nephroblastoma/*genetics/metabolism | 2 | 14.0 |
Research Support, U.S. Gov't, P.H.S. | 15 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Comparative Study | 5 | 0.0 |
Dosage Compensation (Genetics) | 2 | 1.0 |
Tumor Cells, Cultured | 11 | 0.0 |
X Chromosome/genetics | 5 | 2.0 |
Base Sequence | 12 | 0.0 |
Exons/genetics | 2 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
Blotting, Southern | 3 | 0.0 |
DNA/genetics | 2 | 0.0 |
Face/*abnormalities | 2 | 5.0 |
Gene Deletion | 3 | 0.0 |
Growth Disorders/*genetics | 6 | 10.0 |
Linkage (Genetics) | 3 | 0.0 |
Mutation | 4 | 0.0 |
Pedigree | 5 | 0.0 |
Phenotype | 5 | 0.0 |
Syndrome | 16 | 0.0 |
Heparan Sulfate Proteoglycan/genetics/*physiology | 2 | 66.0 |
Abnormalities, Multiple/*genetics | 5 | 1.0 |
Heparan Sulfate Proteoglycan/genetics | 2 | 100.0 |
Risk Factors | 2 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Adult | 2 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Apoptosis | 2 | 0.0 |
Cell Division | 3 | 0.0 |
Heparan Sulfate Proteoglycan/*physiology | 2 | 40.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Morphogenesis | 2 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Time Factors | 4 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Cell Line | 7 | 0.0 |
DNA Methylation | 3 | 0.0 |
*Heparan Sulfate Proteoglycan | 18 | 64.0 |
Heparitin Sulfate/*genetics | 13 | 68.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Proteoglycans/*genetics | 12 | 21.0 |
Infant, Newborn | 2 | 0.0 |
Exons | 2 | 0.0 |
*Sequence Deletion | 3 | 0.0 |
Heparitin Sulfate/metabolism | 3 | 7.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Sequence Alignment | 3 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Genotype | 3 | 0.0 |
Heparitin Sulfate/genetics | 2 | 66.0 |
Proteoglycans/genetics | 2 | 8.0 |
X Chromosome/*genetics | 4 | 1.0 |
Chromosome Mapping | 6 | 0.0 |
English Abstract | 2 | 0.0 |
*X Chromosome | 3 | 0.0 |
Kinetics | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Abnormalities, Multiple/genetics | 2 | 2.0 |
Transcription, Genetic | 3 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Aged | 3 | 0.0 |
Ligands | 2 | 0.0 |
Insulin-Like Growth Factor II/metabolism | 2 | 7.0 |
Solubility | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Protein Binding | 2 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Gene Expression Profiling | 2 | 0.0 |
Transfection | 2 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Gene Expression | 2 | 0.0 |
Membrane Proteins/*genetics/metabolism | 2 | 1.0 |
Neoplasm Proteins/*genetics/metabolism | 2 | 1.0 |
alpha-Fetoproteins/metabolism | 2 | 2.0 |
Middle Aged | 2 | 0.0 |